Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Wave Life Sciences USA, Inc.

< Previous 1 2 Next >
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Tickers WVE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.